NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02594371,"Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer",https://clinicaltrials.gov/study/NCT02594371,,COMPLETED,To determine the safety and tolerability of Oraxol as compared to IV paclitaxel in metastatic breast cancer,NO,Metastatic Breast Cancer,DRUG: Oraxol|DRUG: IV paclitaxel,"Tumor response as determined by response criteria, Tumor response is evaluated using the response evaluation criteria in solid tumors (RECIST v1.1 criteria)., 19 to 22 weeks|Safety and tolerability assessments of Oraxol compared with IV paclitaxel, as determined by laboratory, adverse event (AE) and serious adverse event (SAE) information, Safety assessments will consist of determining and recording all AEs and SAEs; laboratory evaluation of hematology, blood chemistry, and urine analyses; periodic measurement of vital signs and electrocardiograms (ECGs); and the performance of physical examinations, as detailed in the schedule of procedures and assessments of the protocol, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to ~48 months (expected end of study).]","Progression-free survival (PFS), The endpoint of progression-free survival is defined as not having died or progression of disease. Lost to follow-up will be considered as censored., From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to ~48 months (expected end of study).|Overall survival (OS), The endpoint of overall survival is defined as death, confirmed alive, and lost to follow-up. Alive and lost to follow-up will be considered as censored., From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to ~48 months (expected end of study).",,"Athenex, Inc.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,402,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,KX-ORAX-001,2015-12-02,2019-07-25,2022-06-30,2015-11-03,,2022-08-03,"Centro de Investigacion Pergamino SA, Pergamino, Buenos Aires, Argentina|IONC, Ciudad de Córdoba, Cordoba, Argentina|Clinica Universitaria Privada Reina Fabiola, Córdoba, Cordoba, Argentina|Centro Oncologico Infinito, Santa Rosa, La Pampa, Argentina|Fundación Koriza, Santa Rosa, La Pampa, Argentina|Clinica Viedma, Viedma, Rio Negro, Argentina|COIBA, Buenos Aires, Argentina|CEMEDIC, Ciudad Autónoma de Buenos Aires, Argentina|Fundación Investigar, Ciudad Autónoma de Buenos Aires, Argentina|Fundación Centro Oncológico Riojano Integral (CORI), La Rioja, Argentina|Hospital Provincial del Centenario, Santa Fe, Argentina|Instituto de Oncologia de Rosario, Santa Fe, Argentina|Sanatorio Britanico, Santa Fe, Argentina|Centro Medico San Roque, Tucuman, Argentina|CAIPO, Tucumán, Argentina|Fundación Arturo López Pérez, Santiago de Chile, Chile|Hospital de Referencia de Salud Cordillera Unidad de Patología Mamaria, Santiago de Chile, Chile|Hospital San Borja Arriarán, Santiago de Chile, Chile|IRAM, Santiago de Chile, Chile|Clínica Alemana Temuco, Temuco, Chile|Instituto Nacional de Cancerología E.S.E., Bogota, Colombia|Fundación Colombiana de Cancerología Clinica Vida, Medellín, Colombia|Fundación Hospitalaria San Vicente de Paúl, Medellín, Colombia|Hemato Oncologos S.A., Valle, Colombia|Hospital Metropolitano de Santiago (HOMS), Santiago de los Caballeros, Dominican Republic|Clinical Research, Santo Domingo, Dominican Republic|Hospital General de la Plaza de la Salud, Santo Domingo, Dominican Republic|Hospital SOLCA, Guayaquil, Ecuador|Hospital Carlos Andrade Martín, Quito, Ecuador|Hospital SOLCA, Quito, Ecuador|Espemedic, San Salvador, El Salvador|Hospital Diagnotico Clinica Oncologica & Cancer Research, San Salvador, El Salvador|American Cancer Center, Guatemala City, Guatemala|CELAN Clínica Médica, Guatemala City, Guatemala|Clinica Privada, Guatemala city, Guatemala|Clínica Privada, Guatemala City, Guatemala|Grupo Angeles, S.A., Guatemala City, Guatemala|Oncomedica en Guatemala, Guatemala City, Guatemala|CRESEM, Quetzaltenango, Guatemala|Excel Medica, Cortés, Honduras|Tecnología en Investigación, Cortés, Honduras|Centro Hemato Oncológico Panamá, Panama city, Panama|Clínica Oncológica Miraflores, Lima, Peru|Hospital Cayetano Heredia, Lima, Peru|Hospital Nacional del Arzobispo Loayza, Lima, Peru",
